Opioid-induced constipation (OIC) is one of the most distressing side effects seen in palliative care patients.5,6
- OIC can cause or result in abdominal pain, nausea and vomiting, or fecal impaction.5,6
- OIC can last the entire time that a palliative care patient with advanced illness is taking opioid medication.2,7
Learn about the mechanism and treatment of OIC in the palliative care setting:
- About Opioids and Constipation
Get more details on the constipating effects of opioids - Managing Opioid-Induced Constipation (OIC)
Review the current treatment options for managing OIC
OIC in advanced illness patients contributes to an Click to find out morealready challenging medical condition.3
Indication
RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR
beyond 4 months has not been studied.
Important Safety Information for RELISTOR
- RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
- Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients. Use RELISTOR with caution in patients with known or suspected lesions of the GI tract
- Use of RELISTOR has not been studied in patients with peritoneal catheters
- The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), diarrhea (5.5% vs 2.4%), and hyperhidrosis (6.7% vs 6.5%)
- Safety and efficacy of RELISTOR have not been established in pediatric patients
Please see the full Prescribing Information.
